Technology
Health
Medical

Atossa Genetics

$2.54
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.

+$0.02 (0.79%) Today
$0.00 (0.00%) After Hours

Why Robinhood?

You can buy or sell ATOS and other stocks, options, ETFs, and crypto commission-free!

About

Atossa Genetics, Inc. operates as a clinical-stage pharmaceutical company, which focuses on the development of novel therapeutics and delivery methods for the treatment of breast cancer and other breast conditions. It offers ForeCYTE and ArgusCYTE diagnostic tests. Read More The ForeCYTE Breast Health Test provides personalized information about the 10-year and lifetime risk of breast cancer for women between ages 18 and 65. The ArgusCYTE Breast Health Test offers information to help inform breast cancer treatment options and to help monitor potential recurrence. The company was founded by Steven C. Quay and Shu Chih Chen in December 2008 and is headquartered in Seattle, WA.

Employees
4
Headquarters
Seattle, Washington
Founded
2008
Market Cap
23.17M
Price-Earnings Ratio
Dividend Yield
0.00
Average Volume
1.11M
High Today
$2.56
Low Today
$2.45
Open Price
$2.50
Volume
69.53K
52 Week High
$7.39
52 Week Low
$0.80

Collections

Technology
Health
Medical
Cancer Prevention
Pharmaceutical
Therapy
US
North America

News

NasdaqApr 25

Atossa Genetics Provides Clinical Update at the 4th Annual Precision: Breast Cancer World R&D Summit

Atossa Genetics Provides Clinical Update at the 4th Annual Precision: Breast Cancer World R&D Summit SEATTLE, April 25, 2019 (GLOBE NEWSWIRE) -- Atossa Genetics Inc. (NASDAQ:ATOS), a clinical-stage biopharmaceutical company developing novel therapeutics and delivery methods for breast cancer and other breast conditions, announced that today Steven C. Quay, M.D., Ph.D., Atossa's President and CEO, is providing an update on the Company's clinical programs at the Precision: Breast Cancer World R&D Summit at...

2,338
Markets InsiderApr 23

6 Top Gainers In Healthcare Sector (ATOS, AKTX, ATHX...)

(RTTNews) - The following are some of today's top gainers in the pharma/biotech sector. 1. Atossa Genetics Inc. (ATOS) Atossa Genetics is a clinical-stage biopharmaceutical company developing novel therapeutics for breast cancer and other breast conditions. Gained 22.97% to close Tuesday's (Apr.23) trading at $3.48. News: No news Pipeline: Atossa has two development programs: Endoxifen (topical and oral forms) and a program for the targeted delivery of drugs and immunotherapies via its proprietary int...

888
Seeking AlphaApr 23

Atossa up 27% ahead of Endoxifen presentation

Nano cap Atossa Genetics (ATOS +26.9% ) is up on more than 80% higher volume in the early going. Shares have rallied 41% since Friday. On Thursday, April 25, President & CEO Steven Quay, M.D., Ph.D. will deliver a presentation at the Precision: Breast Cancer World R&D Summit in Boston titled "A Twenty-First Century Approach: From Primary Prevention to Intraductal Immunotherapy" that should include the company's development plan and outlook for endoxifen....

1,078

Earnings

-$2.90
-$1.93
-$0.97
$0.00
Q3 2017
Q4 2017
Q1 2018
Q2 2018
Q3 2018
Q4 2018
Q1 2019
Estimated
-$0.63 per share
Actual
-$0.62 per share

Popular Stocks

All investments involve risk and the past performance of a security, or financial product does not guarantee future results or returns. Securities offered through Robinhood Financial LLC, member FINRA/SIPC. To learn more about the information provided on this page, please see our Web Disclosures.